Rituximab and mycophenolate mofetil may offer the most effective off-label alternatives for NMOSD patients, according to a study.| Neuromyelitis News
Rituximab safely and effectively treated sudden interstitial lung disease in a man with undiagnosed primary Sjögren’s syndrome.| Sjogren's Syndrome News